Article

FDA expands Intracorneal lens trial

The FDA has approved the expansion of the clinical trial of Anamed Inc.'s Perma-Vision intracorneal lens for the correction of hyperopia up to +6 D.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
John Saharek, president of ImprimisRX, speaks with Ophthalmology Times' David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting
What keeps you up at night in ophthalmology: Part II
Chris Adams, Diopter Corp CEO
Ramin Valian, of Allergan, discusses pharmaceuticals in the glaucoma industry at Glaucoma 360
© 2025 MJH Life Sciences

All rights reserved.